{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T05:07:12Z","timestamp":1769749632666,"version":"3.49.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pregnancy Hypertension"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.preghy.2022.05.001","type":"journal-article","created":{"date-parts":[[2022,5,8]],"date-time":"2022-05-08T01:13:15Z","timestamp":1651972395000},"page":"1-6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Comparison of intravenous labetalol and hydralazine for severe hypertension in pregnancy in Northeastern Nigeria: A randomized controlled trial"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5683-5646","authenticated-orcid":false,"given":"Sagir","family":"Muhammad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hadiza","family":"Usman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yahaya Musa","family":"Dawha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anisah","family":"Yahya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayoola","family":"Yekeen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1047-8334","authenticated-orcid":false,"given":"Babagana","family":"Bako","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.preghy.2022.05.001_b0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pmed.1002783","article-title":"The incidence of pregnancy hypertension in India, Pakistan, Mozambique, and Nigeria: a prospective population-level analysis","volume":"16","author":"Magee","year":"2019","journal-title":"Plos Med."},{"key":"10.1016\/j.preghy.2022.05.001_b0010","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.preghy.2013.08.001","article-title":"Hydralazine vs labetalol for the treatment of severe hypertensive disorders of pregnancy. A randomized, controlled trial","volume":"4","author":"Delgado De Pasquale","year":"2014","journal-title":"Pregnancy Hypertens."},{"key":"10.1016\/j.preghy.2022.05.001_b0015","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4314\/eamj.v86i1.46924","article-title":"Maternal mortality at the State Specialist Hospital Bauchi, Northern Nigeria","volume":"86","author":"Mairiga","year":"2009","journal-title":"East Afr. Med. J."},{"key":"10.1016\/j.preghy.2022.05.001_b0020","first-page":"72","article-title":"Trends in maternal mortality at the Lagos University Teaching Hospital, Lagos, Nigeria","volume":"22","author":"Olamijulo","year":"2012","journal-title":"Nig. Q J. Hosp. Med."},{"key":"10.1016\/j.preghy.2022.05.001_b0025","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1517\/14740338.2015.998197","article-title":"Labetalol for hypertension in pregnancy","volume":"14","author":"Magee","year":"2015","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.preghy.2022.05.001_b0030","doi-asserted-by":"crossref","first-page":"568","DOI":"10.4103\/2141-9248.122112","article-title":"Maternal mortality at Federal Medical Centre Yola, Adamawa State: a five-year review","volume":"3","author":"Bukar","year":"2013","journal-title":"Ann. Med. Health Sci. Res."},{"key":"10.1016\/j.preghy.2022.05.001_b0035","first-page":"147","article-title":"Trends in maternal mortality at University of Maiduguri teaching hospital, Maiduguri, Nigeria \u2013 a five year review -","volume":"51","author":"Audu","year":"2010","journal-title":"Niger Med J."},{"key":"10.1016\/j.preghy.2022.05.001_b0040","first-page":"1","article-title":"Cerebrovascular dysfunction in preeclamptic pregnancies","volume":"17","author":"Hammer","year":"2016","journal-title":"Curr. Hypertens. Rep."},{"key":"10.1016\/j.preghy.2022.05.001_b0045","first-page":"767","article-title":"Severe hypertension in pregnancy: using dynamic checklists to save lives, South African","volume":"106","author":"Moodley","year":"2016","journal-title":"Med. J."},{"issue":"540","key":"10.1016\/j.preghy.2022.05.001_b0050","first-page":"e1","article-title":"Neonatal outcome of pregnancies complicated by hypertensive disorders between 34 and 37 weeks of gestation: A 7 year retrospective analysis of a national registry","volume":"205","author":"Langenveld","year":"2011","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.preghy.2022.05.001_b0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmj.327.7421.955","article-title":"Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis","volume":"327","author":"Magee","year":"2003","journal-title":"Br. Med. J."},{"key":"10.1016\/j.preghy.2022.05.001_b0060","first-page":"1","article-title":"Drugs for treatment of very high blood pressure during pregnancy (Review)","author":"Duley","year":"2013","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.preghy.2022.05.001_b0065","first-page":"1","article-title":"A comparison of hydralazine and labetalol in the management of severe preeclampsia","volume":"3","author":"Nombur","year":"2014","journal-title":"J Women\u2019s Heal. Care."},{"key":"10.1016\/j.preghy.2022.05.001_b0070","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ejogrb.2006.02.015","article-title":"Severe hypertension in pregnancy: Hydralazine or labetalol. A randomized clinical trial","volume":"128","author":"Vigil-De Gracia","year":"2006","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"10.1016\/j.preghy.2022.05.001_b0075","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ultrasmedbio.2010.10.006","article-title":"Changes in fetal and maternal doppler parameters observed during acute severe hypertension treatment with hydralazine or labetalol: A randomized controlled trial","volume":"37","author":"Baggio","year":"2011","journal-title":"Ultrasound Med. Biol."},{"key":"10.1016\/j.preghy.2022.05.001_b0080","first-page":"466","article-title":"Comparison of hydralazine and labetalol to lower severe hypertension in pregnancy, Pakistan","volume":"33","author":"Khan","year":"2017","journal-title":"J. Med. Sci."},{"issue":"1","key":"10.1016\/j.preghy.2022.05.001_b0085","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3109\/10641955.2015.1117098","article-title":"Risks of parenteral antihypertensive therapy for the treatment of severe maternal hypertension are low","volume":"35","author":"Sharma","year":"2016","journal-title":"Hypertens. Pregnancy."},{"issue":"5","key":"10.1016\/j.preghy.2022.05.001_b0090","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1007\/s13224-017-1053-9","article-title":"Comparison of efficacy and safety of intravenous labetalol versus hydralazine for management of severe hypertension in pregnancy","volume":"68","author":"Patel","year":"2018","journal-title":"J. Obstet. Gynecol. India."},{"key":"10.1016\/j.preghy.2022.05.001_b0095","first-page":"3996","article-title":"A comparative study of hydralazine versus labetalol in the management of pregnancy induced hypertension (PIH)","volume":"4","author":"Nabanita","year":"2016","journal-title":"Sch. J. Appl. Med. Sci."},{"issue":"1","key":"10.1016\/j.preghy.2022.05.001_b0100","doi-asserted-by":"crossref","first-page":"22","DOI":"10.21276\/obgyn.2017.4.1.5","article-title":"A comparative study of intravenous hydralazine versus labetalol in the management of severe hypertension in pregnancyA comparative study of intravenous hydralazine versus labetalol in the management of severe hypertension in pregnancy","volume":"4","author":"Singh","year":"2017","journal-title":"New Indian J. OBGYN"},{"key":"10.1016\/j.preghy.2022.05.001_b0105","doi-asserted-by":"crossref","unstructured":"C. Mmom, R. Ogu, N. Orazulike, S. Uzoigwe, Intravenous hydrallazine or intravenous labetalol in severe hypertension in pregnancy: a randomized clinical trial, Obstet. Gynecol. Int. J. 6 (2017) 1\u20134. DOI: 10.15406\/ogij.2017.06.00222.","DOI":"10.15406\/ogij.2017.06.00222"},{"issue":"12","key":"10.1016\/j.preghy.2022.05.001_b0110","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1111\/1471-0528.16319","article-title":"A core outcome set for pre-eclampsia research: an international consensus development study","volume":"127","author":"Duffy","year":"2020","journal-title":"BJOG An Int. J. Obstet. Gynaecol."},{"key":"10.1016\/j.preghy.2022.05.001_b0115","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.21276\/sjams.2016.4.6.80","article-title":"A Comparative study of IV Labetalol and IV Hydralazine on mean arterial blood pressure changes in pregnant women with hypertensive emergency","volume":"4","author":"Swati","year":"2016","journal-title":"Sch. J. Appl. Med. Sci."},{"issue":"11","key":"10.1016\/j.preghy.2022.05.001_b0120","doi-asserted-by":"crossref","DOI":"10.1007\/s11906-014-0489-x","article-title":"Cardiovascular risks associated with diastolic blood pressure and isolated diastolic hypertension","volume":"16","author":"Li","year":"2014","journal-title":"Curr. Hypertens. Rep."},{"key":"10.1016\/j.preghy.2022.05.001_b0125","doi-asserted-by":"crossref","unstructured":"J.J. Martin, B. Thigpen, R. Moore, C. Rose, J. Cushman, W. May, Stroke and severe preeclampsia and eclampsia: a paradigm shift focusing on systolic blood pressure, Obstet. Gynecol. 105 (2005) 246\u201354. https:\/\/doi.org\/10.1097\/01.AOG.0000151116.84113.56.PMID:15684147.","DOI":"10.1097\/01.AOG.0000151116.84113.56"},{"key":"10.1016\/j.preghy.2022.05.001_b0130","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/jhh.2016.50","article-title":"A prediction model for the response to oral labetalol for the treatment of antenatal hypertension","volume":"31","author":"Stott","year":"2016","journal-title":"J. Hum. Hypertens."},{"key":"10.1016\/j.preghy.2022.05.001_b0135","first-page":"1","article-title":"Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial","volume":"6736","author":"Easterling","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.preghy.2022.05.001_b0140","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.preghy.2019.09.019","article-title":"First-line antihypertensive treatment for severe hypertension in pregnancy: a systematic review and network meta-analysis","volume":"18","author":"Alavifard","year":"2019","journal-title":"Pregnancy Hypertens."}],"container-title":["Pregnancy Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210778922000447?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210778922000447?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:56:22Z","timestamp":1761897382000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210778922000447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":28,"alternative-id":["S2210778922000447"],"URL":"https:\/\/doi.org\/10.1016\/j.preghy.2022.05.001","relation":{},"ISSN":["2210-7789"],"issn-type":[{"value":"2210-7789","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of intravenous labetalol and hydralazine for severe hypertension in pregnancy in Northeastern Nigeria: A randomized controlled trial","name":"articletitle","label":"Article Title"},{"value":"Pregnancy Hypertension","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.preghy.2022.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 International Society for the Study of Hypertension in Pregnancy. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}